BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10471318)

  • 21. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus.
    McPherson JP; Brown GA; Goldenberg GJ
    Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
    Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural and functional analysis of the control region of the human DNA topoisomerase II alpha gene in drug-resistant cells.
    Takano H; Ise T; Nomoto M; Kato K; Murakami T; Ohmori H; Imamura T; Nagatani G; Okamoto T; Ohta R; Furukawa M; Shibao K; Izumi H; Kuwano M; Kohno K
    Anticancer Drug Des; 1999 Apr; 14(2):87-92. PubMed ID: 10405635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells.
    Gromova I; Biersack H; Jensen S; Nielsen OF; Westergaard O; Andersen AH
    Biochemistry; 1998 Nov; 37(47):16645-52. PubMed ID: 9843432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.
    Hopfner R; Mousli M; Jeltsch JM; Voulgaris A; Lutz Y; Marin C; Bellocq JP; Oudet P; Bronner C
    Cancer Res; 2000 Jan; 60(1):121-8. PubMed ID: 10646863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.
    Feldhoff PW; Mirski SE; Cole SP; Sullivan DM
    Cancer Res; 1994 Feb; 54(3):756-62. PubMed ID: 8306338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.
    Cowell IG; Okorokov AL; Cutts SA; Padget K; Bell M; Milner J; Austin CA
    Exp Cell Res; 2000 Feb; 255(1):86-94. PubMed ID: 10666337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
    Lok CN; Lang AJ; Mirski SE; Cole SP
    Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
    Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
    Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.
    Yoon JH; Kim JK; Rha GB; Oh M; Park SH; Seong RH; Hong SH; Park SD
    Biochem J; 1999 Dec; 344 Pt 2(Pt 2):367-74. PubMed ID: 10567217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.
    Mo YY; Beck WT
    Oncol Res; 1997; 9(4):193-204. PubMed ID: 9268990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
    Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
    Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
    Zhou Z; Guan H; Kleinerman ES
    Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line.
    Mirski SE; Cole SP
    Cancer Res; 1995 May; 55(10):2129-34. PubMed ID: 7743513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
    Kim HD; Tomida A; Ogiso Y; Tsuruo T
    J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear distribution of human DNA topoisomerase IIbeta: a nuclear targeting signal resides in the 116-residue C-terminal tail.
    Cowell IG; Willmore E; Chalton D; Marsh KL; Jazrawi E; Fisher LM; Austin CA
    Exp Cell Res; 1998 Sep; 243(2):232-40. PubMed ID: 9743583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
    Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
    Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of two nuclear import signals in the alpha-gene product ICP22 of herpes simplex virus 1.
    Stelz G; Rücker E; Rosorius O; Meyer G; Stauber RH; Spatz M; Eibl MM; Hauber J
    Virology; 2002 Apr; 295(2):360-70. PubMed ID: 12033795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
    Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
    Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.